Evidence map›Paper›PMID 32820647›Full record

ArticleClinical trials (London, England)2020

Recruitment, retention, and adherence in a clinical trial: The Pediatric Heart Network's Marfan Trial experience.

Michelle S Hamstra, Victoria L Pemberton, Nicholas Dagincourt, Danielle Hollenbeck-Pringle, Felicia L Trachtenberg, James F Cnota, Andrew M Atz, Elizabeth Cappella, Sylvia De Nobele, Josephine Grima and 11 more

Open access · greenAbstract read
In one paragraph

Article in Clinical trials (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Randomized pilot study comparing standard vs high-calorie feeding in infants with Neonatal Opioid Withdrawal Syndrome.Journal of perinatology : official journal of the California Perinatal Association · 2026
    Article
  2. Determinants of Infant Participation and Non-Participation in Primary Prevention Trials.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 15 institutions in 3 countries.

Michelle S HamstraHeart Institute Administration, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.ORCID 0000-0002-0018-057X
Victoria L PembertonNational Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA.
Nicholas DagincourtNew England Research Institutes, Inc., Watertown, MA, USA.
Danielle Hollenbeck-PringleNew England Research Institutes, Inc., Watertown, MA, USA.
Felicia L TrachtenbergNew England Research Institutes, Inc., Watertown, MA, USA.
James F CnotaHeart Institute Administration, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.ORCID 0000-0001-6732-8949
Andrew M AtzMedical University of South Carolina, Charleston, SC, USA.
Elizabeth CappellaAnn and Robert H. Lurie Children's Hospital, Chicago, IL, USA.
Sylvia De NobeleGhent University Hospital, Ghent, Belgium.
Josephine GrimaThe Marfan Foundation, Port Washington, NY, USA.
Martha KingHarvard Medical School, Boston Children's Hospital, Boston, MA, USA.
Rosalind KorsinChildren's Hospital of New York, New York, NY, USA.
Linda M LambertPrimary Children's Hospital, University of Utah, Salt Lake City, UT, USA.
Meghan K MacNealIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Larry W MarkhamThe Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, USA.
Gretchen MacCarrickJohns Hopkins School of Medicine, Baltimore, MD, USA.
Donna M SylvesterChildren's Hospital of Philadelphia, Philadelphia, PA, USA.
Patricia WalterHospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Mingfen XuDuke University School of Medicine, Durham, NC, USA.
Ronald V LacroHarvard Medical School, Boston Children's Hospital, Boston, MA, USA.
Pediatric Heart Network Investigators
New England Research Institutes · USBoston Children's Hospital · USCincinnati Children's Hospital Medical Center · USChildren's Hospital of Philadelphia · USDuke University · USGhent University Hospital · BEIcahn School of Medicine at Mount Sinai · USJohns Hopkins University · USLurie Children's Hospital · USMarfan Foundation · USMedical University of South Carolina · USMonroe Carell Jr. Children's Hospital · USNational Heart Lung and Blood Institute · USPrimary Children's Hospital · USUniversity of Toronto · CA

Funding

Support for QA/QC for Prior Approval ProcessUL1TR002553 · NCATS · DUKE UNIVERSITY · PI LI, JENNIFER S, MCNAMARA, JAMES O. · 2018 to 2023
$58.5M
Pediatric Heart network DCCU10HL068270 · NHLBI · NEW ENGLAND RESEARCH INSTITUTES, INC. · PI MILLER, JULIE ELAINE, TRACHTENBERG, FELICIA LYNN · 2011 to 2016
$44.9M
Ventricular Volumes and Varability (VVV)U01HL068270 · NHLBI · NEW ENGLAND RESEARCH INSTITUTES, INC. · PI SLEEPER, LYNN A · 2001 to 2010
$40.3M
MIS-C Program: Data Coordinating Center for the Pediatric Heart Network MIS-C ProgramU24HL135691 · NHLBI · NEW ENGLAND RESEARCH INSTITUTES, INC. · PI MILLER, JULIE ELAINE, TRACHTENBERG, FELICIA LYNN · 2017 to 2024
$37.9M
Pediatric Heart Network: Follow-up of the Single Ventricle Reconstruction TrialU01HL068290 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LAI, WYMAN W · 2001 to 2010
$4.1M
Pediatric Heart Disease Network: CHOP MembershipU01HL068279 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI VETTER, VICTORIA L · 2001 to 2010
$3.7M
Randomized Therapeutic Trials in Pediatric Heart DiseaseU01HL068285 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI NEWBURGER, JANE W. · 2001 to 2010
$3.4M
Randomized Clinical Trials for Pediatric Heart DiseaseU01HL068281 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI SAUL, J PHILIP · 2001 to 2010
$3.2M
Clinical and genomic responses to remote ischemic preconditioningU01HL068288 · NHLBI · HOSPITAL FOR SICK CHLDRN (TORONTO) · PI MCCRINDLE, BRIAN W · 2001 to 2010
$3.0M
Intermountain Pediatric Heart Disease Research CenterU01HL068292 · NHLBI · UNIVERSITY OF UTAH · PI MINICH, L. LUANN · 2001 to 2010
$2.7M
The Duke-UNC-CH Pediatric Cardiology Clinical CenterU01HL068269 · NHLBI · DUKE UNIVERSITY · PI LI, JENNIFER S · 2001 to 2010
$2.6M
Pediatric Heart Network - The Hospital for Sick Children, TorontoUG1HL135680 · NHLBI · HOSPITAL FOR SICK CHLDRN (TORONTO) · PI MCCRINDLE, BRIAN W, MITAL, SEEMA · 2017 to 2023
$1.7M
NCATS NIH HHS UL1 TR002553NHLBI NIH HHS U01 HL068269NHLBI NIH HHS U01 HL068270NHLBI NIH HHS U01 HL068279NHLBI NIH HHS U01 HL068281NHLBI NIH HHS U01 HL068285NHLBI NIH HHS U01 HL068288NHLBI NIH HHS U01 HL068290NHLBI NIH HHS U01 HL068292NHLBI NIH HHS U01 HL085057NHLBI NIH HHS U10 HL068270NHLBI NIH HHS U24 HL135691NHLBI NIH HHS UG1 HL135680
6 · The paper itself

Abstract

BACKGROUND/

aimsThe Pediatric Heart Network Marfan Trial was a randomized trial comparing atenolol versus losartan on aortic root dilation in 608 children and young adults with Marfan syndrome. Barriers to enrollment included a limited pool of eligible participants, restrictive entry criteria, and a diverse age range that required pediatric and adult expertise. Retention was complicated by a 3-year commitment to a complex study and medication regimen. The Network partnered with the Marfan Foundation, bridging the community with the research. The aims of this study are to report protocol and medication adherence and associated predictive factors, and to describe recruitment and retention strategies.

methodsRecruitment, retention, and adherence to protocol activities related to the primary outcome were measured. Retention was measured by percentage of enrolled participants with 3-year outcome data. Protocol adherence was calculated by completion rates of study visits, ambulatory electrocardiography (Holter monitoring), and quarterly calls. Medication adherence was assessed by the number of tablets or the amount of liquid in bottles returned. Centers were ranked according to adherence (high, medium, and low tertiles). Recruitment, retention, and adherence questionnaires were completed by sites. Descriptive statistics summarized recruitment, retention, and adherence, as well as questionnaire results. Regression modeling assessed predictors of adherence.

resultsCompletion rates for visits, Holter monitors, and quarterly calls were 99%, 94%, and 96%, respectively. Primary outcome data at 3 years were obtained for 88% of participants. The mean percentage of medication taken was estimated at 89%. Site and age were associated with all measures of adherence. Young adult and African American participants had lower levels of adherence. Higher adherence sites employed more strategies; had more staffing resources, less key staff turnover, and more collaboration with referring providers; utilized the Foundation's resources; and used a greater number of strategies to recruit, retain, and promote protocol and medication adherence.

conclusionOverall adherence was excellent for this trial conducted within a National Institutes of Health-funded clinical trial network. Strategies specifically targeted to young adults and African Americans may have been beneficial. Many strategies employed by higher adherence sites are ones that any site could easily use, such as greeting families at non-study hospital visits, asking for family feedback, providing calendars for tracking schedules, and recommending apps for medication reminders. Additional key learnings include adherence differences by age, race, and site, the value of collaborative learning, and the importance of partnerships with patient advocacy groups. These lessons could shape recruitment, retention, and adherence to improve the quality of future complex trials involving rare conditions.

Indexed as

Patient SelectionAdolescentAnti-Arrhythmia AgentsAtenololBlack or African AmericanChildChild, PreschoolClinical ProtocolsDrug MonitoringFemaleHumansInfantLosartanMaleMarfan SyndromePatient ComplianceAnti-Arrhythmia AgentsAtenololLosartanadherenceclinical trialMarfan syndromerecruitmentretention

Identifiers

PMID32820647
PMCPMC7664172
OpenAlexW3080650048

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.